COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I FLVFLV REGNR2 LY-CoVLY RemdesivirRMD
HCQ study #76 of 257
6/30 Late treatment study
Mikami et al., J. Gen. Intern. Med., doi:10.1007/s11606-020-05983-z (Peer Reviewed)
Risk Factors for Mortality in Patients with COVID-19 in New York City
Source   PDF   Share   Tweet
HCQ decreases mortality, HR 0.53 (CI 0.41–0.67). IPTW adjustment does not significantly change HR 0.53 (0.41-0.68). Retrospective 6,000 patients in New York City.

Mikami et al., 6/30/2020, retrospective, USA, North America, peer-reviewed, 7 authors.
risk of death, 47.0% lower, RR 0.53, p < 0.001, treatment 575 of 2077 (27.7%), control 231 of 743 (31.1%), adjusted per study.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 257 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit